Skip to content

Teladoc Health TDOC Raw materials and purchased parts

Other financials

Income statement

See full
Revenue$613.8M-2.5%
Gross profit$416.3M-3.8%
Operating income-$61.8M+48.8%
Net income-$63.8M+31.4%
EPS (diluted)-$0.36+32.1%

Balance sheet

See full
Cash & equivalents$750.7M-37.1%
Total debt$42.2M-92.9%
Total equity$1.3B-6.4%
Total assets$2.8B-18.5%

Cash flow

See full
Operating cash flow$9.5M-40.2%
CapEx$1.7M-39.1%
Free cash flow$7.9M-40.5%

Valuation

See full
Market cap$1.41B+16.5%
Enterprise value$701.31M+14.7%
P/S0.6×+0.1×

Profitability

See full
Gross margin69.3%-1.2pp
Operating margin-8.1%-3.6pp
Net margin-6.8%-3.1pp
FCF margin11.1%-0.2pp

Returns & leverage

See full
Return on equity-12.4%-5.4pp
Debt / equity-0.4×
Current ratio2.8×+1.1×

Where this comes from

Reported directly by Teladoc Health in its filing.

Tagged under the XBRL concept tdoc:InventoryRawMaterialsAndPurchasedPartsGross.

The official record: Teladoc Health’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Teladoc Health's raw materials and purchased parts.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Teladoc Health's raw materials and purchased parts?
Teladoc Health (TDOC) reported raw materials and purchased parts of $11.28M in Q1 2026.
How has Teladoc Health's raw materials and purchased parts changed year-over-year?
Teladoc Health's raw materials and purchased parts decreased by 15.3% year-over-year, from $13.32M to $11.28M.
What is the long-term trend for Teladoc Health's raw materials and purchased parts?
Over 3 years (2022 to 2025), Teladoc Health's raw materials and purchased parts has grown at a -22.9% compound annual growth rate (CAGR), from $30.13M to $13.78M.